The stock is trading above the analyst consensus price target with negative implied upside and an unfavorable risk-to-reward configuration, while quality sits fractionally below the minimum acceptable threshold and revenue is contracting 6% year over year — conditions that make the current entry unfavorable for new capital even though free-cash-flow conversion is strong at 177% of net income and near-term price momentum remains elevated.
Thesis pillars
- Stock Above Consensus Target Negative Asymmetry↓Deteriorating
- Quality Marginally Below Floor→Stable
- Revenue Declining Six Percent↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Fresenius Medical Care AG (FMS) Stock Analysis
Momentum Cont setup
Healthcare · Medical Care Facilities
Sell if holding. Engine safety override at $23.19: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 4.75; Below-average business quality.
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis... Read more
Sell if holding. Engine safety override at $23.19: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 4.75; Below-average business quality. Chart setup: Trend continuation, RSI 59, MACD bullish. Score 4.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 110d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Nov 5, 2026Recent Developments — Fresenius Medical Care AG
Latest news
- NEWS Bernstein Research lowers price target for Fresenius Medical Care — fiscal.ai Nov 5, 2026 negative
- NEWS CEO Clarifies Impact of FDA Inspection at Melrose Park Facility — fiscal.ai Nov 4, 2026 neutral
- NEWS Fresenius Medical Care AG & Co. KGaA Q3 2026 Earnings Date and Estimates - MarketBeat — MarketBeat Nov 2, 2026 neutral
- NEWS FMs of N. Korea, Switzerland hold talks in Pyongyang - Yonhap News Agency — Yonhap News Agency Oct 31, 2026 neutral
- NEWS Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Price Breaks Above 200 Day Moving Average - Should You Sell? - Mar — MarketBeat Oct 30, 2026 neutral
Latest item Nov 5, 2026 · Generated 2026-11-05T12:04:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.19: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 4.75; Below-average business quality. Chart setup: Trend continuation, RSI 59, MACD bullish. Prior stop was $21.97. Score 4.7/10, moderate confidence.
Analyst target $20.50 reached (−11.6% from $23.19); no take-profit level is published. Prior stop was $21.97. Stop-loss: $21.97.
Target reached (-11.6% upside); Quality below floor (2.5 < 4.0).
Fresenius Medical Care AG trades at a P/E of 13.4 (forward 7.6). TrendMatrix value score: 7.6/10. Verdict: Sell.
29 analysts rate FMS, with a consensus score of 2.8/5. 7 analysts publish price targets averaging $24.
What does Fresenius Medical Care AG do?Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the...
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.